Enable Biosciences is an early stage firm developing a patent-pending technology platform designed to enable ultra-sensitive antibody detection for research and clinical applications.The firm's core technology is Antibody Detection by Agglutination-PCR, or ADAP, a platform developed at UC Berkeley and Stanford. Licensed by enable from Berkeley, ADAP assays are true ultrasensitive assays and are many multiples more sensitive than standard immunoassays. An early application of the technology under development is an ultrasensitive non-radioactive autoantibody test that can be readily used for population screening --offering the potential for improved outcomes in type 1 diabetes, Enable Biosciences is working on an at-home collection method to establish the likelihood of progressing to type 1 diabetes to prevent DKA and promote preventive therapies. Dried blood spot samples are easily collected in the convenience of an individual's home, promoting screening by improving testing compliance and reducing costs by making it easier to store and ship samples. Current work builds upon previous research efforts at Enable and Stanford with support from the NIDDK and JDRF, the world's largest private funder of type 1 diabetes research.
